The document provides guidance on selecting anticoagulation treatment for acute venous thrombosis. It recommends low molecular weight heparin (LMWH) as preferred for cancer and liver disease or coagulopathy. Vitamin K antagonist (VKA) is preferred for renal disease with creatinine clearance below 30, and atrial fibrillation with coronary artery disease. Apixaban, rivaroxaban, edoxaban, and dabigatran are options but associated with higher risk of dyspepsia or gastrointestinal bleed than VKA or apixaban. LMWH is recommended for pregnancy.